Cardio3 BioSciences Enrolls First Patient in Phase I Trial for NKG2D CAR T-Cell
April 13, 2015 11:45 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, April 13, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels:CARD) (Paris:CARD), a leader in engineered cell-therapy treatments with clinical programs initially...
Cardio3 BioSciences Receives USPTO Notice of Allowance for First U.S. Patent Broadly Covering TCR-Deficient T-Cells Engineered to Express a Chimeric Antigen Receptor
April 07, 2015 12:17 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, April 7, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels:CARD) (Paris:CARD), a leader in engineered cell therapies with clinical programs initially targeting...
Cardio3 BioSciences Announces Intention to Conduct a Registered Public Offering in the United States
March 31, 2015 17:30 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, March 31, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels:CARD) (Paris:CARD), a leader in engineered cell therapies with clinical programs initially...
Cardio3 BioSciences Successfully Completes Futility Analysis of Lead Cardiac Cell Therapy, C-Cure(R)
March 30, 2015 01:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, March 30, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels:CARD) (Paris:CARD), a leader in engineered cell therapy treatments, today announced the successful...
Cardio3 BioSciences Reports 2014 Financial and Operating Results
March 26, 2015 06:05 ET
|
Celyad
Significant Progress Made in Building a Global Specialty Therapeutics Company
Conference Call to be Held on 26 March 2015 at 2.00 p.m. CET / 9.00 a.m. ET
Expansion into the CAR T-cell space...
Cardio3 BioSciences to Open New Manufacturing Facility in Rochester, MN to Support CHART-2 Phase III Trial and U.S. Growth
March 23, 2015 02:00 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, March 23, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels:CARD) (Paris:CARD), a leader in the discovery and development of engineered cell therapies, today...
Cardio3 BioSciences to Present at 3rd Annual Regen Med Investor Day
March 18, 2015 13:05 ET
|
Celyad
MONT-SAINT-GUIBERT, Belgium, March 18, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences (C3BS) (Brussels:CARD) (Paris:CARD), a leader in the discovery and development of specialized cell therapies, today...